rs201323717
Positions:
Variant summary
Our verdict is Likely benign. Variant got -1 ACMG points: 2P and 3B. PM2BP4_ModerateBS1_Supporting
The NM_017433.5(MYO3A):āc.1174T>Cā(p.Ser392Pro) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000076 in 1,605,728 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (ā ā ).
Frequency
Genomes: š 0.00034 ( 0 hom., cov: 33)
Exomes š: 0.000049 ( 0 hom. )
Consequence
MYO3A
NM_017433.5 missense
NM_017433.5 missense
Scores
3
12
4
Clinical Significance
Conservation
PhyloP100: 1.93
Genes affected
MYO3A (HGNC:7601): (myosin IIIA) The protein encoded by this gene belongs to the myosin superfamily. Myosins are actin-dependent motor proteins and are categorized into conventional myosins (class II) and unconventional myosins (classes I and III through XV) based on their variable C-terminal cargo-binding domains. Class III myosins, such as this one, have a kinase domain N-terminal to the conserved N-terminal motor domains and are expressed in photoreceptors. The protein encoded by this gene plays an important role in hearing in humans. Three different recessive, loss of function mutations in the encoded protein have been shown to cause nonsyndromic progressive hearing loss. Expression of this gene is highly restricted, with the strongest expression in retina and cochlea. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Likely_benign. Variant got -1 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
BP4
Computational evidence support a benign effect (MetaRNN=0.106755584).
BS1
Variant frequency is greater than expected in population amr. gnomad4 allele frequency = 0.000335 (51/152164) while in subpopulation AMR AF= 0.00333 (51/15294). AF 95% confidence interval is 0.00261. There are 0 homozygotes in gnomad4. There are 44 alleles in male gnomad4 subpopulation. Median coverage is 33. This position pass quality control queck. Existence of Clinvar submissions makes me limit the strength of this signal to Supporting
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
MYO3A | NM_017433.5 | c.1174T>C | p.Ser392Pro | missense_variant | 13/35 | ENST00000642920.2 | NP_059129.3 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
MYO3A | ENST00000642920.2 | c.1174T>C | p.Ser392Pro | missense_variant | 13/35 | NM_017433.5 | ENSP00000495965.1 | |||
MYO3A | ENST00000543632.5 | c.1174T>C | p.Ser392Pro | missense_variant | 12/17 | 1 | ENSP00000445909.1 | |||
MYO3A | ENST00000642197.1 | n.1378T>C | non_coding_transcript_exon_variant | 13/27 | ||||||
MYO3A | ENST00000647478.1 | n.1174T>C | non_coding_transcript_exon_variant | 12/30 | ENSP00000493932.1 |
Frequencies
GnomAD3 genomes AF: 0.000335 AC: 51AN: 152046Hom.: 0 Cov.: 33
GnomAD3 genomes
AF:
AC:
51
AN:
152046
Hom.:
Cov.:
33
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.000184 AC: 46AN: 250094Hom.: 1 AF XY: 0.000126 AC XY: 17AN XY: 135220
GnomAD3 exomes
AF:
AC:
46
AN:
250094
Hom.:
AF XY:
AC XY:
17
AN XY:
135220
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000488 AC: 71AN: 1453564Hom.: 0 Cov.: 30 AF XY: 0.0000387 AC XY: 28AN XY: 723562
GnomAD4 exome
AF:
AC:
71
AN:
1453564
Hom.:
Cov.:
30
AF XY:
AC XY:
28
AN XY:
723562
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.000335 AC: 51AN: 152164Hom.: 0 Cov.: 33 AF XY: 0.000592 AC XY: 44AN XY: 74382
GnomAD4 genome
AF:
AC:
51
AN:
152164
Hom.:
Cov.:
33
AF XY:
AC XY:
44
AN XY:
74382
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ExAC
AF:
AC:
14
ClinVar
Significance: Uncertain significance
Submissions summary: Uncertain:4
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Dec 19, 2020 | In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Has not been previously published as pathogenic or benign to our knowledge - |
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 11, 2024 | This sequence change replaces serine, which is neutral and polar, with proline, which is neutral and non-polar, at codon 392 of the MYO3A protein (p.Ser392Pro). This variant is present in population databases (rs201323717, gnomAD 0.1%). This variant has not been reported in the literature in individuals affected with MYO3A-related conditions. ClinVar contains an entry for this variant (Variation ID: 450770). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt MYO3A protein function with a negative predictive value of 80%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Oct 09, 2018 | The p.Ser392Pro variant in MYO3A has been identified by our laboratory in 1 ind ividual with hearing loss. It has also been identified in 0.13% (45/34322) of La tino chromosomes, including 1 homozygote, by gnomAD (http://gnomad.broadinstitut e.org) and has been reported in ClinVar (Variation ID 450770). Computational pre diction tools and conservation analysis suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogen icity. In summary, the clinical significance of the p.Ser392Pro variant is uncer tain. ACMG/AMP Criteria applied: BS1_Supporting, PP3. - |
Inborn genetic diseases Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Aug 15, 2023 | The c.1174T>C (p.S392P) alteration is located in exon 13 (coding exon 11) of the MYO3A gene. This alteration results from a T to C substitution at nucleotide position 1174, causing the serine (S) at amino acid position 392 to be replaced by a proline (P). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
BayesDel_addAF
Benign
T
BayesDel_noAF
Uncertain
CADD
Pathogenic
DANN
Uncertain
DEOGEN2
Uncertain
T;T;D
Eigen
Uncertain
Eigen_PC
Uncertain
FATHMM_MKL
Pathogenic
D
LIST_S2
Uncertain
.;D;D
M_CAP
Uncertain
D
MetaRNN
Benign
T;T;T
MetaSVM
Uncertain
D
MutationAssessor
Uncertain
M;M;.
PrimateAI
Benign
T
PROVEAN
Uncertain
.;D;D
REVEL
Pathogenic
Sift
Uncertain
.;D;T
Sift4G
Uncertain
.;D;D
Polyphen
D;D;D
Vest4
0.73, 0.73
MVP
0.94
MPC
0.38
ClinPred
T
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at